Trevena Announces FDA Has Set PDUFA Date of August 7, 2020 for Oliceridine FDA considers NDA resubmission a complete Class 2 response Updated guidance on extended cash runway, funding operations into Q1 2021 CHESTERBROOK, Pa., March 05, 2020 (GLOBE NEWSWIRE) -- Trevena,...

Trevena Resubmits New Drug Application for Oliceridine CHESTERBROOK, Pa., Feb. 10, 2020 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...

Trevena Advances NDA Resubmission Activities for Oliceridine — Completed enrollment in healthy volunteer QT study, topline data expected in Q4 2019 — — Completed characterization of inactive metabolite — — Remains on track to resubmit NDA in Q1 2020 — ...